Preferred Provider Among Small, Mid-Size and Large Biopharmaceutical Customers
ME NewsWire/ Business Wire
RESEARCH TRIANGLE PARK, N.C. - Thursday, April 17th 2014
For the second year in a row, Quintiles has been named the industry leader that best differentiates itself on service quality for Phase II/III research in Industry Standard Research’s (ISR) 2014 CRO Quality Benchmarking Phase II/III Service Providers Report. According to the 148 pharmaceutical and biotechnology decision makers surveyed by ISR in this year’s report, Quintiles is the preferred provider for Phase II/III research among small, mid-size and large biopharmaceutical companies.
“At Quintiles, we are focused on leading our customers through an increasingly complex and ever-changing drug development landscape,” said Paula Brown Stafford, president of Clinical Development at Quintiles. “We are delighted once again to be recognized as the industry leader in Phase II/III research. This distinction is a result of the work of our tremendous teams around the world and underscores our unique ability to connect insights, expertise and capabilities across our organization to improve the probability of success for our customers.”
In the survey, Quintiles outperformed all other large CROs across all customer loyalty-related measures, which are defined by overall satisfaction, willingness to recommend, and likelihood to use Quintiles again. Quintiles also rated higher than all large CROs in a number of selection criteria, including:
Breadth of services
Therapeutic expertise
Commercial market, local market and regulatory knowledge
Data quality
Technology for real-time data access
Speed of site start-up
Patient recruitment strategy
Survey respondents were decision-makers with large, mid-size and small biopharmaceutical companies who were involved in outsourced clinical study activities and Phase II/III clinical trials within the past 18 months. More information about the ISR report is available here.
About Quintiles
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 28,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Contacts
Quintiles
Mari Mansfield, Media Relations, +1.919.998.2639 (office) or +1.919.259.3298 (mobile)
mari.mansfield@quintiles.com
Karl Deonanan, Investor Relations, +1.919.998.2789
InvestorRelations@quintiles.com
Permalink: http://www.me-newswire.net/news/10718/en
ME NewsWire/ Business Wire
RESEARCH TRIANGLE PARK, N.C. - Thursday, April 17th 2014
For the second year in a row, Quintiles has been named the industry leader that best differentiates itself on service quality for Phase II/III research in Industry Standard Research’s (ISR) 2014 CRO Quality Benchmarking Phase II/III Service Providers Report. According to the 148 pharmaceutical and biotechnology decision makers surveyed by ISR in this year’s report, Quintiles is the preferred provider for Phase II/III research among small, mid-size and large biopharmaceutical companies.
“At Quintiles, we are focused on leading our customers through an increasingly complex and ever-changing drug development landscape,” said Paula Brown Stafford, president of Clinical Development at Quintiles. “We are delighted once again to be recognized as the industry leader in Phase II/III research. This distinction is a result of the work of our tremendous teams around the world and underscores our unique ability to connect insights, expertise and capabilities across our organization to improve the probability of success for our customers.”
In the survey, Quintiles outperformed all other large CROs across all customer loyalty-related measures, which are defined by overall satisfaction, willingness to recommend, and likelihood to use Quintiles again. Quintiles also rated higher than all large CROs in a number of selection criteria, including:
Breadth of services
Therapeutic expertise
Commercial market, local market and regulatory knowledge
Data quality
Technology for real-time data access
Speed of site start-up
Patient recruitment strategy
Survey respondents were decision-makers with large, mid-size and small biopharmaceutical companies who were involved in outsourced clinical study activities and Phase II/III clinical trials within the past 18 months. More information about the ISR report is available here.
About Quintiles
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 28,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Contacts
Quintiles
Mari Mansfield, Media Relations, +1.919.998.2639 (office) or +1.919.259.3298 (mobile)
mari.mansfield@quintiles.com
Karl Deonanan, Investor Relations, +1.919.998.2789
InvestorRelations@quintiles.com
Permalink: http://www.me-newswire.net/news/10718/en
No comments:
Post a Comment